Potential Adverse Effect of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate
暂无分享,去创建一个
J. Kanis | E. McCloskey | M. Lorentzon | L. Vandenput | H. Johansson | N. Harvey | E. Liu | Zhang Zheng
[1] T. Powles,et al. Clodronate. , 2020, Bone.
[2] H. Takeuchi,et al. Effect of acetaminophen on osteoblastic differentiation and migration of MC3T3-E1 cells , 2018, Pharmacological reports : PR.
[3] B. Cryer,et al. Overuse and Misperceptions of Nonsteroidal Anti‐inflammatory Drugs in the United States☆, ☆☆ , 2016, The American journal of the medical sciences.
[4] Kuo-Chin Huang,et al. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study , 2016, BMC Musculoskeletal Disorders.
[5] Mel S. Lee,et al. Chronic NSAIDs Use Increases the Risk of a Second Hip Fracture in Patients After Hip Fracture Surgery , 2015, Medicine.
[6] C. Cooper,et al. Ankylosing Spondylitis Is Associated With an Increased Risk of Vertebral and Nonvertebral Clinical Fractures: A Population‐Based Cohort Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] L. Idolazzi,et al. Medication Use Before and After Hip Fracture: A Population-Based Cohort and Case-Control Study , 2014, Drugs & Aging.
[8] J. O'Connor,et al. NSAID therapy effects on healing of bone, tendon, and the enthesis. , 2013, Journal of applied physiology.
[9] P. Vestergaard,et al. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS) , 2012, Osteoporosis International.
[10] P. Sambrook,et al. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.
[11] R. Eastell,et al. Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.
[12] C. Midgett,et al. Prostacyclin: An Inflammatory Paradox , 2011, Front. Pharmacol..
[13] R. Lindsay,et al. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors , 2011, Osteoporosis International.
[14] F. Blyth,et al. Lifestyle factors, medications, and disease influence bone mineral density in older men: findings from the CHAMP study , 2011, Osteoporosis International.
[15] T. Powles,et al. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. , 2010, European journal of cancer.
[16] J. Kanis,et al. Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate , 2009, Osteoporosis International.
[17] C. Cooper,et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates , 2009, Osteoporosis International.
[18] S. van der Linden,et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study , 2008, Annals of the rheumatic diseases.
[19] J. Kanis,et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.
[20] J. Kanis,et al. Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] Toshitaka Nakamura,et al. Selective cyclooxygenase-2 inhibitor prevents reduction of trabecular bone mass in collagen-induced arthritic mice in association with suppression of RANKL/OPG ratio and IL-6 mRNA expression in synovial tissues but not in bone marrow cells , 2008, Journal of Bone and Mineral Metabolism.
[22] John Brazier,et al. Clodronate Reduces the Incidence of Fractures in Community‐Dwelling Elderly Women Unselected for Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled Randomized Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] S. Rodeo,et al. Indomethacin and Celecoxib Impair Rotator Cuff Tendon-to-Bone Healing , 2006, The American journal of sports medicine.
[24] T. Powles,et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] , 2006, Breast Cancer Research.
[25] J. Kanis,et al. Clodronate Reduces Vertebral Fracture Risk in Women With Postmenopausal or Secondary Osteoporosis: Results of a Double‐Blind, Placebo‐Controlled 3‐Year Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] A. Pilotto,et al. NSAID and Aspirin Use by the Elderly in General Practice , 2003, Drugs & aging.
[27] C. Cooper,et al. Utility of medical and drug history in fracture risk prediction among men and women. , 2002, Bone.
[28] L. Pylkkänen,et al. The absolute bioavailability of clodronate from two different oral doses. , 2002, Bone.
[29] J. Woo,et al. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclastogenesis in vitro. , 2002, Biochemical pharmacology.
[30] J. Kanis,et al. Long‐term follow‐up of a prospective, double‐blind, placebo‐controlled randomized trial of clodronate in multiple myeloma , 2001, British journal of haematology.
[31] R. Jones,et al. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. , 2001, The American journal of medicine.
[32] O. Johnell,et al. The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.
[33] C. Cooper,et al. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. , 2000, Bone.
[34] U. Lerner,et al. Bone resorbing activity released from zymosan-activated mouse peritoneal macrophages - the role of prostanoids and interleukin-1 , 1999, Inflammation Research.
[35] Dunn,et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma , 1998, British journal of haematology.
[36] T. Powles,et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.
[37] M. Nevitt,et al. Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[38] J. Mucklow,et al. Studies of the oral bioavailability of alendronate , 1995, Clinical pharmacology and therapeutics.
[39] T. Powles,et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] H. Sinzinger,et al. Enhancement of human dental cyst PGI2 formation by platelet derived growth factor and its role in cyst growth and bone resorption. , 1989, Archives of oral biology.
[41] B. Thomson,et al. The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. , 1985, Endocrinology.